Drug profile · INN
denileukin diftitox-cxdl
LYMPHIR
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
denileukin diftitox-cxdl (LYMPHIR) is an FDA-listed pharmaceutical active ingredient. Associated with Citius Pharmaceuticals. Route of administration: injection. Current US regulatory status: approved.
Key facts
Frequently asked questions
What is denileukin diftitox-cxdl?
denileukin diftitox-cxdl (LYMPHIR) is an FDA-listed pharmaceutical active ingredient. Associated with Citius Pharmaceuticals. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for denileukin diftitox-cxdl?
LYMPHIR is a marketed brand name for denileukin diftitox-cxdl. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of denileukin diftitox-cxdl?
denileukin diftitox-cxdl has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.